What Is Dementia? — Snow That Settles Without a Sound, a Branch Beginning to Bend

"You keep forgetting lately"

I am on the phone with my seventy-four-year-old mother, and she asks a question again that she asked ten minutes ago. When I ask if she took her blood pressure medication, there is a pause and she says, "I must have taken it." I also heard that she got quite confused last month while handling some banking business. After I hang up, a single word lingers in my head: dementia.

Dementia is the name for a state where the ability to remember and judge has dropped compared to before, making it difficult to manage daily life on one's own. Dementia is the name of a state, and the diseases that create that state are many.

Starting from that flicker of forgetfulness, this article looks in turn at what dementia is, what causes dementia, and how far drugs, care, and prevention have come.

Between Forgetfulness and Dementia

As people age, names may take longer to pop into mind, or learning new things may require more time. Some of these changes are expected as part of the normal aging process (PMID 39485649). An increase in forgetfulness alone does not mean someone has dementia.

Cognitive function is a term that groups together mental tasks such as remembering, understanding speech, planning, and judging. When cognitive functions, including memory and language, decline to the point where it interferes with managing daily life, that is a symptom of dementia (PMID 39485649).

Even among daily activities, tasks that involve multiple steps—such as preparing meals or managing money—use several cognitive functions at once. Managing money can be one of the very first tasks to change at the stage when cognitive function begins to decline slightly (PMID 22053873).

Age is the single largest risk factor for dementia (PMID 41533411). In an analysis combining 47 studies published from 1985 to 2019, about 697 out of 10,000 community residents aged 50 and older had dementia (about 7%), and the number of people with dementia increased sharply with age, from 27 per 10,000 in their 50s to 6,592 per 10,000 at age 100 and older (PMID 31884487). Flip this number around, and more than nine out of ten people aged 50 and older do not have dementia. The risk rises steeply with age, but getting older does not mean everyone will develop it.

Early signs of dementia are easy to miss or simply dismiss as a result of aging (PMID 41533411). Confirmation is made through medical evaluation and tests. It starts with a brief screening test and a questionnaire answered by a family member or friend, and if cognitive function appears to be impaired, a more detailed cognitive test is performed. Medications are reviewed, vision, hearing, nutrition, and neurological status are checked, and other causes are ruled out through blood tests for things like vitamin B12 or thyroid function, alongside a brain MRI (magnetic resonance imaging). Distinguishing between reversible conditions like depression and dementia is an essential step in this evaluation (PMID 41533411).

Forgetfulness that has increased slowly and confusion that arose suddenly are different stories. Dementia is portrayed as a functional decline that progresses over time (PMID 33863461). Delirium is a state of clouded consciousness and scattered attention that can look similar to dementia. People with dementia are prone to developing delirium (PMID 33863461), and delirium is one of the reversible conditions that must be distinguished from dementia (PMID 41533411). Delirium is an acute state of disturbed attention and cognition, accompanied by a high risk of complications and death (PMID 32222295). Because it can look like long-standing dementia while masking an underlying physical illness or poisoning, it is treated as a true medical emergency (PMID 10767881). Unlike changes that pile up slowly, if consciousness becomes clouded or attention scatters suddenly, that change may be an emergency situation different from deepened dementia, and confirmation is made immediately through medical evaluation and tests (PMID 10767881).

What separates dementia is less the forgetfulness itself, and more whether cognitive function has declined to the point where managing daily life independently has become difficult.

The Diseases That Cause Dementia

Neurons are the basic cells of the brain and nervous system that receive electrical signals and pass them on to the next cell. Alzheimer's disease is a brain disease in which neurons slowly break down, and it is the most common cause of dementia. One review paper noted that 60 to 80% of dementia is Alzheimer's disease (PMID 39485649), and in an analysis pooling community-based studies, out of 697 people with dementia per 10,000 people aged 50 and older, Alzheimer's disease accounted for 324, which is just under half (PMID 31884487). Because overlapping diseases are common, this share varies depending on diagnostic criteria and the studied population (PMID 35678405). An early decline in the ability to remember recent events is a hallmark of this disease (PMID 39485649).

The remaining types of dementia are also named after the underlying diseases that cause them. Vascular dementia is dementia caused by blood vessels in the brain blocking, bursting, or becoming damaged, which injures the brain tissue that received that blood. It is the second most common dementia after Alzheimer's disease (PMID 38513772). Areas where brain tissue has died or blood has leaked remain as its hallmarks (PMID 35678405). Stroke, where blood to the brain is suddenly blocked or bursts, is also one of the causes.

Lewy body dementia is dementia caused by clumps of a protein called alpha-synuclein forming inside neurons. In this dementia, hallucinations—seeing things that are not actually there—are particularly distressing for caregivers (PMID 28795386).

Frontotemporal dementia is dementia caused by the breakdown of neurons in the frontal lobes (at the front of the brain) and temporal lobes (on the sides). In the behavioral variant, agitation, aggression, and an inability to control impulses stand out, and becoming numb to other people's emotions makes caregiving more difficult (PMID 28795386).

In actual aging brains, these diseases frequently overlap rather than occurring entirely on their own. Alzheimer's disease changes often coexist with vascular damage or Lewy bodies, which is why it can be difficult to cleanly pin down a single disease diagnosis during life (PMID 35678405).

Dementia is a state produced by several diseases, among which Alzheimer's disease is the most common.

What Piles Up Before Symptoms

The name of this disease comes from Dr. Alois Alzheimer, the physician who first made it known in 1906 (PMID 41386339). The two changes he noted in his 1907 paper—lumps outside nerve cells and tangled threads inside them—remain central to diagnosing this disease after death (PMID 34729690).

What forms the lumps outside is amyloid beta. Amyloid beta is a small protein fragment made by nerve cells that, when not cleared away in time, tangles together and piles up as lumps outside nerve cells. The amyloid hypothesis views the imbalance between how much of this fragment is made and how much is cleared away as a very early, often initiating factor in Alzheimer's disease. While debate continues over this hypothesis, a 2016 review evaluated the amyloid beta imbalance as the most broadly validated therapeutic target (PMID 27025652). The genotype (APOE4) that raises Alzheimer's disease risk hinders amyloid beta from being cleared in the brain (PMID 27025652).

What forms the threads inside is tau. Tau is a protein that holds up the cell's skeleton inside nerve cells; in Alzheimer's disease, its shape changes and it tangles like threads inside the cell. A synapse is the joint where one nerve cell passes a signal to the next nerve cell. As amyloid lumps and tau tangles pile up and spread, synapses fail to do their job and nerve cells disappear, and at the end of that, cognitive impairment appears and deepens (PMID 39620836).

This change starts long before symptoms. When following the same people over a long time with various test indicators, Alzheimer's disease has a long latent period that continues for decades before symptoms appear (PMID 37202518). The brain and spinal cord are bathed in a clear fluid called cerebrospinal fluid. The change where amyloid beta in this cerebrospinal fluid drops and amyloid becomes visible on PET (positron emission tomography) scans comes years ahead of other signs (PMID 27025652).

The order becomes clear if you picture snow piling up on pine tree branches on a winter night. Snow falls silently, and the branch holds out for a while as if nothing is happening. It is a long time later that it starts to bend noticeably. The decades when amyloid beta and tau pile up are the time when snow falls, and the time when memory wavers and daily life becomes difficult is when the branch starts to bend.

The analogy holds true up to this point. In an aging brain, burdens like blood vessel damage or other proteins often pile on alongside this snow. And it is not rare to find older people who have these changes in the brain yet have no problems with cognitive function (PMID 35678405). There are branches that bend less even while carrying the same weight.

Ways to measure what is piling up in living people have also emerged. Amyloid beta and tau in cerebrospinal fluid drawn from the lower back reflect the core changes of this disease and provide useful information for diagnosis even at an early stage (PMID 30051512). Methods using PET to image amyloid piled up in the brain are also used (PMID 21342022). Methods measuring it with blood were evaluated in a 2018 review as a promising stage needing more validation (PMID 30051512), and a 2023 review notes that more precise blood measurements helped open up trials targeting the presymptomatic stage (PMID 37202518).

Alzheimer's disease begins decades before symptoms appear, with amyloid beta and tau piling up in the brain.

The Gray Zone, Mild Cognitive Impairment

There are people whose memory test scores come out lower than their peers, but who still manage grocery shopping and money management on their own. Mild cognitive impairment is a state where cognitive function has declined enough to show up on tests, but everyday life is still managed without help from others. It differs from dementia in that help is not yet needed for daily tasks (PMID 25514304). In an analysis pooling 66 studies and roughly 240,000 people, 15.56% of community residents aged 50 and older—about one in six—had mild cognitive impairment, and that proportion was higher at older ages and lower with higher levels of education (PMID 35977150).

It is a time when looking closely at a branch might make it seem slightly bent. However, what presses on that branch is not always the eye of Alzheimer's disease. Among the causes of mild cognitive impairment are those that can be treated, and finding those causes can lead to improvement (PMID 27042901). Depression, taking multiple medications together, and uncontrolled cardiovascular risk factors are cited as causes to examine together (PMID 25514304). Cases where people feel their memory has declined due to causes unrelated to a disease that damages nerve cells are also mixed within the name of mild cognitive impairment (PMID 32791521).

Next comes a three-way split. In an analysis following 89 studies for an average of 5.2 years, the people who progressed to dementia were 41.5% in hospital-recruited cohorts and 27.0% in community-based cohorts. Those who remained stable were about half in both groups (49.3%, 49.8%), and those who reverted to normal were 8.7% in the hospital group and 28.2% in the community group (PMID 40078377). In a 2009 analysis pooling 41 studies, about 5 to 10% progressed to dementia each year, and the authors concluded that based on this rate, most would not progress to dementia even after 10 years of follow-up (PMID 19236314). The numbers vary greatly depending on where the people were recruited from; the more hospital-based the cohort, the higher the rate of progression to dementia and the lower the rate of reversion (PMID 40078377, PMID 26908276).

There are still no drugs proven to delay or prevent progression from mild cognitive impairment to dementia (PMID 28689566). A 2014 clinical review noted that aerobic exercise, intellectually engaging activities, and socializing with others can help reduce the risk of further decline (PMID 25514304).

Using testing to check for and disclose amyloid at an asymptomatic or mild stage comes with dilemmas. Conflicting considerations—such as how accurate and useful the result is, the right not to know, and the risks of misunderstanding, stigma, and discrimination—are being sorted out (PMID 35144684).

Mild cognitive impairment can be a gateway to dementia, but even after years of follow-up, a substantial number of people remain stable or return to normal.

What Medicines Do

Medicines for Alzheimer's disease have for decades been one branch that manages symptoms (PMID 42801246). Neurotransmitters are chemical messengers that nerve cells release to send signals to other cells, usually crossing from a synapse to the cell on the other side. Acetylcholine is one such neurotransmitter, and in Alzheimer's disease, the nerve cells that use acetylcholine are damaged (PMID 36996971). Cholinesterase inhibitors are a class of drugs that slow the breakdown of acetylcholine in the synapse, leaving that signal around a little longer.

The basis for using this class in Alzheimer's dementia from mild to severe stages is solid, and the main effects are slowing the decline in cognition and daily functioning and delaying the onset of difficult-to-manage behavioral symptoms. For moderate and more advanced stages, another class of drugs that works in a different way is used with more limited evidence (PMID 39620846). The benefits of these drugs are small and do not change the progression of the disease itself (PMID 42801246). Trials compare the medicines to a placebo. A placebo is a fake medicine that looks the same but contains no active medical ingredients. When pooling trials that combined patients with mild cognitive impairment and mild Alzheimer's disease, only anti-amyloid antibodies slowed progression compared to a placebo, while this class did not (PMID 40316479). Some analyses suggest that as follow-up gets longer, the effect fades until no benefit remains (PMID 41760397, PMID 41988809). This is a different tone from reviews that consider the evidence for the dementia stage solid. The numbers showing how large the effect of this class is in the dementia stage are not available in the data for this article.

Anti-amyloid antibodies are a class of drugs that attach to amyloid-beta clumps built up in the brain and clear them out. In 2023, one drug in this class received full approval from the US Food and Drug Administration (FDA), and another received similar approval in 2024 (PMID 39620846). Targeting the underlying disease process of amyloid, it is evaluated as the first treatment to slow disease progression, albeit by a small amount, in a statistically meaningful way (PMID 42801246).

The target group is people whose symptoms have just begun. Trials have enrolled patients with mild cognitive impairment caused by Alzheimer's disease or mild Alzheimer's disease (PMID 40316479), and confirming the presence of amyloid in the brain has been a condition for entering the trials (PMID 36447240). MRIs and PET scans are used to screen whether a person is eligible for this drug and to monitor for side effects (PMID 39620843).

The size of the effect is also compared with a placebo. In one analysis pooling seven trials, the group that received this drug had a rate of decline in cognition and daily functioning about 27.6% slower than the placebo group, which was calculated as delaying disease progression by about 5.5 months over 19.5 months (PMID 41760397). In another analysis pooling 8,010 participants from seven trials (average age 71.5 years), progression was slower than with a placebo, but the difference fell short of the minimum size a patient would notice. The difference from the placebo on a combined score of cognition and daily functioning was 0.41 points, whereas the threshold set for a meaningful difference was 1 point (PMID 40316479). In the same analysis, this class slowed progression slightly more than cholinesterase inhibitors (PMID 40316479).

The effects come with risks. Amyloid-related imaging abnormalities are changes that appear on an MRI while taking anti-amyloid antibodies, referring to places where the brain has swelled or bled. Commonly called ARIA for short, they can be serious and require monitoring with scheduled MRIs (PMID 39620846). People who inherited the risk genotype we saw earlier from both parents had about 5.5 times the odds of developing the brain-swelling type of abnormality compared to those who did not, and developing this abnormality did not mean the drug worked any better. Safety indicators excluding ARIA—meaning serious adverse events and death—did not differ from cholinesterase inhibitor trials, and ARIA is a risk measured separately for antibodies alone (PMID 40316479).

Our understanding of how useful and worthwhile this class is for patients is still in its infancy (PMID 39620846). The clinical significance of long-term use, costs, and equitable access remain open questions (PMID 42801246).

Looking at it like snow on a branch, this drug is close to brushing off the snow piled on a branch. The brushed branch bent less quickly, but the difference is small, and there is also the risk of damaging the branch while brushing.

Anti-amyloid antibodies slowed progression compared to a placebo in early Alzheimer's disease, but the difference fell short of the minimum size a patient would notice, and side effects of brain swelling or bleeding must be monitored with MRIs.

The Caregiver

Beside a person with dementia, there is usually family. Among 14,919 family caregivers who participated in 47 studies, 70% were women, and spouses (44%) and children (43%) made up the vast majority (PMID 40784129). Family caregivers of people with dementia are called "the invisible second patient." While caregiving has positive sides, it generally carries a heavy burden, followed at high rates by depression, social isolation, physical illness, and economic hardship (PMID 19585957). Because some results show that caregiving provides meaning and purpose that link to better health, the impact of caregiving on health does not point in just one direction (PMID 37898293).

The burden grows beyond memory problems. Behavioral and psychological symptoms are changes in mind and behavior—such as apathy, depression, agitation, aggression, hallucinations, delusions, and sleep problems—that appear in dementia alongside cognitive issues like memory. Apathy and depression are the most common, and agitation, aggression, and hallucinations and delusions can be particularly distressing and dangerous for the patient and the caregiver (PMID 31727229). These symptoms best predict caregiving burden and caregiver depression, and among them, agitation, aggression, and impulsive behaviors are the greatest contributors. One reason for this is that these behaviors disrupt the emotional connection between the caregiver and the person receiving care (PMID 28795386).

For these symptoms, non-drug approaches are recommended as the first treatment in most cases. This is because the evidence for drugs is small, inconsistent, and carries a greater risk of harm, though drugs can be used cautiously when symptoms are dangerous or extremely distressing (PMID 31727229). Checking for underlying physical illnesses is the first step, and training care staff has been cited as the most effective intervention (PMID 31264056). In advanced dementia, logic and persuasion often do not work well, whereas conversations that give a sense of having choices work better (PMID 33863461).

Ways to help caregivers have also been tested. In an analysis of 85 randomized trials, case management, education on the disease and caregiving, and multi-component programs reduced caregiving burden (PMID 35247788). The effects of these interventions are generally small (effect sizes 0.09–0.23), and even when the burden itself is not greatly reduced, mood or coping capacity often improves (PMID 24618967). Female caregivers felt a greater burden than male caregivers, with a small difference of an effect size of 0.21 (PMID 40784129). Caregiving burden strongly predicts when a person with dementia will be moved to a nursing facility (PMID 33417236).

Behavioral and psychological symptoms and caregiver burden are also part of what dementia creates, and interventions to ease them, however small their effects, have been confirmed by trials.

Modifiable Risk Factors

There is an estimate that 14 modifiable risk factors account for roughly 45% of worldwide dementia, and that eliminating all of those factors could prevent that much of it. This is a number put forward in a 2024 report by a dementia commission assembled by the medical journal The Lancet (PMID 40423572, PMID 41004922). Unlike age or inborn genes, a modifiable risk factor is one that can be reduced through lifestyle, medical treatment, or social efforts. The 12 factors chosen by the commission's 2020 report included things like diabetes, depression, social isolation, obesity, and lack of physical activity (PMID 37997052). Family history, heart and blood vessel diseases, and low education levels are also counted as risk factors for dementia (PMID 41533411).

This 45% is an estimate calculating the share that would decrease if those factors all disappeared across the entire population. It does not carry the meaning that if an individual person reduces these factors, their own dementia risk drops by 45%. The likelihood of all the factors disappearing is low, but one review noted that there is evidence that even reducing risk factors just a little brings a meaningful benefit (PMID 40423572).

The Lancet commission's 45% is an estimate of the share that would decrease if risk factors disappeared entirely across the whole population, and does not mean that an individual person prevents that much.

The evidence connecting risk factors to dementia comes mostly from studies that watched people over time. Physical activity is an example. In an analysis pooling 58 studies followed for 1 year or longer, people who moved their bodies a lot had about a 20% lower risk of developing dementia (relative risk 0.80), and that association remained even in studies followed for over 20 years (PMID 35301183). Because people tend to move less once the disease starts, studies with short follow-ups can make cause and effect appear reversed. The authors concluded that even after reducing that influence, physical activity supports the side of being a modifiable protective factor, while also reporting the possibility of publication bias (PMID 35301183). Because these are observational studies, these numbers represent the magnitude of association rather than the magnitude of cause.

The evidence from randomized trials is not yet settled. Trials looking at the effects on cognition of drugs managing blood pressure, cholesterol, and blood sugar, as well as programs addressing multiple lifestyle areas at once, are promising but too early to draw conclusions, and most of the trials targeted older adults in high-income countries (PMID 35000424). Whether diabetes medications reduce dementia risk is also uncertain (PMID 36240668).

The evidence that interventions prompting individuals to change their lifestyle prevent cognitive decline or dementia is still at best modest in strength. As reasons for this, this review pointed to the composition of trial participants, the complex causes of the disease, and the social and commercial environments that cause people to be exposed to risks (PMID 40423572). Meanwhile, there are trend studies showing that the rate at which dementia newly develops by age group has been decreasing over the past several decades in high-income countries (PMID 40423572, PMID 37997052). Evidence has been compiled showing that 26 population-wide policies—such as eliminating tuition fees, plain packaging for cigarette packs, and making ear protection mandatory in loud workplaces—reduce the prevalence of nine of the 12 risk factors from 2020. For diabetes, depression, and social isolation, recommendable policies were not found (PMID 37997052).

Again, Mother's Forgetfulness

Let us return to our starting mother. She repeats the same questions, gets confused about whether she took her medicine, and stumbled once at the bank. Such signs are easy to write off as a result of aging (PMID 41533411). Even so, a few moments of forgetfulness cannot determine what is going on.

Clinical guidelines from the Alzheimer's Association recommend that all physicians, including primary care doctors, evaluate anyone with cognitive symptoms in a structured sequence and share the results with the person and their caregiver (PMID 39713942). The evaluation proceeds by listening to the story, running cognitive tests, and ruling out other causes with medication reviews, blood tests, and brain imaging (PMID 41533411). If the mother's changes appeared suddenly, that shift could be an emergency like delirium—which resembles dementia yet can be reversed (PMID 41533411, PMID 10767881).

If the evaluation comes back as mild cognitive impairment, an analysis following people for an average of 5.2 years showed that 41.5% in clinic-recruited groups progressed to dementia and 8.7% reverted to normal. In community-based groups, 27.0% progressed and 28.2% reverted, while roughly half in both groups stayed the same (PMID 40078377). Fixable causes such as depression or taking multiple medications together are examined as well (PMID 25514304).

If it is confirmed as an early stage caused by Alzheimer's disease, two paths of medication enter the discussion. Cholinesterase inhibitors were evaluated in one review as having solid evidence at the dementia stage, but in trials combining mild cognitive impairment with mild Alzheimer's disease, they showed no clear difference from placebo (PMID 39620846, PMID 40316479). Anti-amyloid antibodies require confirming amyloid first, and while they slowed progression compared to placebo, the magnitude fell short of the minimum a patient would notice, and side effects must be monitored with scheduled MRIs (PMID 40316479, PMID 39620846).

And through all of this process, there is the child. If the mother develops behavioral and psychological symptoms, non-drug approaches are still chosen first (PMID 31727229), alongside interventions such as education and case management that ease the burden on caregivers (PMID 35247788). Which tests to take and which treatments to choose are matters to decide together with the doctor in the consultation room.

Where Else to Look

The clinical significance of long-term use of anti-amyloid antibodies is still unanswered (PMID 42801246), and a 2023 review noted that several Phase 3 trials targeting the presymptomatic stage have begun (PMID 37202518). How far individual-level prevention works is also still under debate (PMID 40423572).

What the lapses that occur with aging are like continues in "The Three Steps of Memory — Putting It In, Keeping It, Taking It Out" and "Forgetting — What Fades and What We Just Can't Get Out". Stroke, which forms the basis of vascular dementia, is covered in "What a Stroke Actually Is — Blocked, Burst, and the Clock", and among vascular risk factors, blood pressure is covered in "What Blood Pressure Measures — Two Numbers, and an Answer That Changes With Where You Measure".

How to read the results of screening tests can be seen in "What a Test Actually Tells You — An Introduction to Sensitivity, Specificity, and Pretest Probability", the difference between brain amyloid decreasing and a patient improving in "Better Numbers, Better Patients? — An Introduction to Surrogate Endpoints", and what the relative figure of being 20% lower actually means in terms of the number of people in "If the Risk Was Cut in Half, How Many Fewer People Got Sick? — Relative and Absolute Risk".

Neurons and synapses continue in "How Do Nerve Cells Send Signals? — A Burning Fuse, a Gap Crossed by Ferry", and the locations of the frontal and temporal lobes in "The Map of the Brain — Neighborhoods with Their Own Jobs, a City Joined by Roads". Parkinson's disease is a topic to be covered further in this series.

Source Papers

• "Cognitive Decline in Alzheimer's Disease." (2025) — PMID 39485649 — While some cognitive changes are expected even in normal aging, in Alzheimer's disease they decline to the point where independent daily living is impossible, Alzheimer's disease accounts for 60% to 80% of dementia, and episodic memory decline is an early hallmark feature.
• "Evaluation of Suspected Dementia." (2025) — PMID 41533411 — Dementia is a neurocognitive disorder that interferes with daily functioning, with age being the greatest risk factor (along with family history, cardiovascular disease, poorly controlled diabetes, and low education), subtle signals are often missed or misattributed to normal aging, and evaluation requires screening, caregiver questionnaires, detailed testing, medication reviews, blood tests (for B12 and thyroid), and MRIs, while strictly differentiating reversible conditions like depression and delirium.
• "An examination of instrumental activities of daily living assessment in older adults and mild cognitive impairment." (2012) — PMID 22053873 — Instrumental activities of daily living (such as meal preparation and financial management) draw on multiple cognitive processes, and financial management ability may be one of the earliest changes in mild cognitive impairment and a strong predictor of progression to dementia.
• "The Prevalence of Dementia: A Systematic Review and Meta-Analysis." (2020) — PMID 31884487 — In 47 studies conducted between 1985 and 2019, the prevalence of dementia among community-dwelling individuals aged 50 and older was 697 per 10,000 (324 for Alzheimer's and 116 for vascular dementia), the number of people with dementia doubles roughly every 5 years, and prevalence is higher in women.
• "Chronic Brain Failure." (2021) — PMID 33863461 — Dementia (chronic brain failure) is a progressive functional decline syndrome, serves as a risk factor for delirium, and can present with similar symptoms, whereas in advanced dementia, logic and persuasion rarely work, and interactions that offer a sense of choice are much more successful.
• "Neuropathology of Dementia Disorders." (2022) — PMID 35678405 — The common pathologies of dementia include amyloid, tau, Lewy body alpha-synuclein, TDP-43, and vascular pathology (infarcts and hemorrhages), these pathologies frequently overlap (mixed pathology), and asymptomatic pathology is common even in older adults without cognitive impairment (reflecting resilience and cognitive reserve).
• "Dementia Caregiver Burden: a Research Update and Critical Analysis." (2017) — PMID 28795386 — Neuropsychiatric symptoms are the strongest predictors of caregiver burden and depression, driven mainly by disruptive behaviors such as agitation, aggression, and disinhibition, with the loss of emotional connection being part of the reason, a burden especially prominent in behavioral variant frontotemporal dementia where patients show bluntness toward others' emotions, while visual hallucinations in Lewy body dementia are also distressing.
• "Unveiling Alzheimer's disease (1901-2025): Historical insights, global burden, biological mechanisms, diagnostics, and therapeutic strategies." (2026) — PMID 41386339 — First described by Alois Alzheimer in 1906, Alzheimer's has a multifactorial etiology involving amyloid, tau, and choline deficiency, alongside antibody approvals and numerous candidate failures (historical review).
• "Neuropathology of Alzheimer's Disease." (2022) — PMID 34729690 — Extracellular plaques and intracellular neurofibrillary tangles from the 1907 paper remain central to post-mortem diagnosis today, pathological processes begin decades before symptoms appear, and other pathologies frequently coexist.
• "The amyloid hypothesis of Alzheimer's disease at 25 years." (2016) — PMID 27025652 — Although debate continues, evidence indicates that an imbalance between amyloid-beta production and clearance is a very early and frequently initiating factor, APOE4 impedes amyloid-beta clearance, low cerebrospinal fluid amyloid-beta 42 and positive amyloid PET precede other signs by many years, and amyloid-beta imbalance is the most widely validated therapeutic target (2016).
• "Diagnosing Alzheimer Disease." (2024) — PMID 39620836 — As amyloid plaques and tau tangles accumulate and spread, they lead to synaptic dysfunction, neuronal loss, and the emergence and progression of cognitive impairment.
• "Detection and treatment of Alzheimer's disease in its preclinical stage." (2023) — PMID 37202518 — Longitudinal biomarker studies demonstrate a long latent period (preclinical Alzheimer's disease) beginning decades before symptoms, and precise plasma measurements have made phase 3 trials in the presymptomatic stage possible (2023).
• "Biomarkers for Alzheimer's disease: current status and prospects for the future." (2018) — PMID 30051512 — Cerebrospinal fluid amyloid-beta 42, total tau, and phosphorylated tau reflect core pathology and provide diagnostic information even at early stages, while plasma biomarkers are promising but require further validation (2018).
• "Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease." (2011) — PMID 21342022 — Amyloid-beta and phosphorylated tau are evaluated via cerebrospinal fluid and PET, with pathological changes beginning years to decades before dementia symptoms.
• "The diagnosis and management of mild cognitive impairment: a clinical review." (2014) — PMID 25514304 — Mild cognitive impairment involves objective cognitive decline not severe enough to require assistance with daily living, affects 10% to 20% of adults aged 65 and older, must be evaluated in the context of depression, polypharmacy, and poorly controlled cardiovascular risks, has no proven effective medications, and benefits from aerobic exercise, mental activity, and social participation in reducing the risk of further decline, with estimated annual conversion rates ranging from under 5% to 20%.
• "Worldwide prevalence of mild cognitive impairment among community dwellers aged 50 years and older: a meta-analysis and systematic review of epidemiology studies." (2022) — PMID 35977150 — Across 66 studies comprising 242,804 individuals, the prevalence of mild cognitive impairment among community dwellers aged 50 and older was 15.56%, increasing with age and decreasing with higher levels of education.
• "Mild Cognitive Impairment." (2016) — PMID 27042901 — Prevalence is 15% to 20% among those aged 60 and older, with annual progression rates of 8% to 15%, and not all mild cognitive impairment is due to Alzheimer's disease, as treatable causes can lead to improvement.
• "Functional cognitive disorder: dementia's blind spot." (2020) — PMID 32791521 — Mild cognitive impairment is an etiologically neutral descriptive term that encompasses non-neurodegenerative causes (functional cognitive disorder), and a substantial proportion of cases do not progress to dementia.
• "The prognosis of mild cognitive impairment: A systematic review and meta-analysis." (2025) — PMID 40078377 — Across 89 studies with an average follow-up of 5.2 years, progression to dementia was 41.5% in hospital settings and 27.0% in community settings, roughly 50% remained stable, and reversion to normal cognition occurred in 8.7% of hospital cases and 28.2% of community cases.
• "Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies." (2009) — PMID 19236314 — In 41 cohorts (2009), the annual conversion rate was approximately 5% to 10%, and most individuals did not progress to dementia even over a 10-year follow-up.
• "Reversion From Mild Cognitive Impairment to Normal Cognition: A Meta-Analysis." (2016) — PMID 26908276 — Across 25 studies, reversion to normal cognition was approximately 24%, with 14% in hospital settings versus 31% in community settings.
• "Mild Cognitive Impairment." (2017) — PMID 28689566 — There are no proven medications to slow or reverse the progression from mild cognitive impairment to dementia, evaluation for reversible causes is important, and evidence suggests lifestyle modifications can be effective.
• "Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review." (2022) — PMID 35144684 — Regarding 26 considerations surrounding the disclosure of presymptomatic or predementia biomarker results (feasibility, utility, right not to know, misunderstandings, stigma, and discrimination), opinions are divided with a heavy weight given to potential harms.
• "Alzheimer's Disease: From Molecular Pathogenesis to Disease-Modifying Therapies and Clinical Implementation in Aging Populations." (2026) — PMID 42801246 — For decades, symptomatic medications like cholinesterase inhibitors and memantine offered only small benefits without altering disease progression, whereas antibodies approved in 2023 and 2024 are the first treatments to show small but significant slowing of clinical decline, though ARIA, costs, long-term clinical significance, and equitable access remain unresolved.
• "Alzheimer's disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs." (2023) — PMID 36996971 — Cognitive decline in Alzheimer's disease is linked to cholinergic neuronal degeneration, and current treatments are primarily symptomatic.
• "Treatment of Alzheimer Disease." (2024) — PMID 39620846 — Cholinesterase inhibitors have robust evidence in mild to severe Alzheimer's dementia for delaying cognitive and functional decline and postponing behavioral problems, memantine has more limited evidence for moderate or worse stages, antibodies received FDA approval in 2023 and 2024, regular MRI monitoring is necessary due to ARIA (edema and hemorrhage), and overall utility and value remain at an early stage of understanding.
• "Cumulative cognitive benefits and brain volume change with anti-amyloid therapies for Alzheimer's disease." (2026) — PMID 41760397 — In 7 antibody trials involving 6,479 participants, cognitive decline measured by the CDR-SOB was slowed by 27.6% relative to placebo, delaying decline by 5.52 months over a 19.5-month period, whereas cholinesterase inhibitors showed small and uncertain effects that ultimately yielded no benefit, leading the authors to conclude that antibodies provide greater cumulative benefit than placebo and inhibitors.
• "Longitudinal Multi-Domain Cognitive Assessment of Anti-Amyloid Monoclonal Antibodies Versus Acetylcholinesterase Inhibitors in Early Alzheimer's Disease: A Systematic Review and Meta-Analysis." (2026) — PMID 41988809 — In randomized trials of mild cognitive impairment and mild Alzheimer's disease, cholinesterase inhibitors showed heterogeneous and small effects that weakened with longer follow-up, whereas antibodies showed relatively consistent effects, warranting caution in interpretation.
• "The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis." (2025) — PMID 40316479 — Across 7 antibody trials involving 8,010 participants (mean age 71.5 years) and 9 inhibitor trials, differences versus placebo fell short of the minimal clinically important difference, with a CDR-SOB of −0.41 (versus a minimal important difference of −1) and an ADAS-Cog of −1.35 (versus −2), antibodies slowed progression slightly more than inhibitors, safety indicators (serious adverse events and mortality) showed no differences, the odds of ARIA-E were 5.53 times higher in APOE4 homozygotes, and the authors concluded the results fell short of the minimal important difference.
• "Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease." (2022) — PMID 36447240 — Lessons from antibody development include establishing amyloid positivity as an entry criterion, as several candidates failed due to side effects or unconfirmed pathology.
• "Neuroimaging in Dementia." (2024) — PMID 39620843 — With antibody approvals, MRI and PET have become crucial for determining treatment eligibility and monitoring side effects, and neuroimaging serves as a core biomarker for neurodegenerative diseases.
• "Sex and gender differences in caregiver burden among family caregivers of persons with dementia: A systematic review and meta-analysis." (2025) — PMID 40784129 — Among 47 studies comprising 14,919 family caregivers (70% women, 44% spouses, 43% children), caregiver burden was significantly greater among women (d=0.21).
• "Family caregivers of people with dementia." (2009) — PMID 19585957 — Family caregivers represent "the invisible second patient," generally experiencing high levels of burden, psychiatric morbidity, social isolation, physical illness, and economic hardship, while psychosocial interventions can reduce burden and depression and delay nursing home placement.
• "Understanding the health effects of caregiving stress: New directions in molecular aging." (2023) — PMID 37898293 — Dementia caregiving is associated with various health risks, though conflicting findings show that some caregiving can be beneficial through the maintenance of health, meaning, and purpose.
• "Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia." (2019) — PMID 31727229 — Behavioral and psychological symptoms (apathy, depression, agitation/aggression, psychotic symptoms, and sleep problems) are common and burdensome, with apathy and depression being the most frequent, medication evidence is weak, inconsistent, and associated with high harms making non-pharmacological approaches the first line in most cases, while careful medication is reserved for dangerous or extremely distressing situations.
• "Management of Behavioral and Psychological Symptoms of Dementia." (2019) — PMID 31264056 — Professional caregiver training is the most effective intervention for behavioral and psychological symptoms, starting with addressing contributing medical issues and prioritizing non-pharmacological approaches.
• "Comparative efficacy of 11 non-pharmacological interventions on depression, anxiety, quality of life, and caregiver burden for informal caregivers of people with dementia: A systematic review and network meta-analysis." (2022) — PMID 35247788 — In a network meta-analysis of 85 randomized trials, case management, psychoeducation, and multi-component interventions were effective for reducing caregiver burden.
• "Caregiver burden: a clinical review." (2014) — PMID 24618967 — Risk factors for caregiver burden include being female, low education, cohabiting, hours of care provided, depression, isolation, financial stress, and lack of choice, interventions show weak to moderate effects, and mood and coping often improve even when burden itself is barely reduced.
• "Remotely delivered information, training and support for informal caregivers of people with dementia." (2021) — PMID 33417236 — In a Cochrane review of 26 trials, caregiver burden was found to be a strong predictor of residential care admission, and while remote interventions may slightly reduce burden compared to information provision alone, they show little difference compared to usual care.
• "Are modifiable risk factors for dementia really modifiable?" (2025) — PMID 40423572 — The 2024 Lancet Commission estimated that eliminating 14 potential risk factors could prevent 45% of dementia worldwide (though feasibility is low), evidence indicates that even small reductions in risk factors yield benefits, evidence for individual-level interventions is modest at best, and declining incidence trends in high-income countries suggest the effectiveness of population-level approaches.
• "Population-level interventions for the primary prevention of dementia: a complex evidence review." (2023) — PMID 37997052 — Evidence suggests that 26 population-level interventions targeting 12 risk factors from the Lancet Commission reduce the prevalence of 9 risk factors (such as abolishing tuition fees, plain tobacco packaging, and mandatory hearing protection equipment), whereas no interventions are recommended for diabetes, depression, or social isolation, alongside declining age-specific incidence in high-income countries.
• "Physical activity as a protective factor for dementia and Alzheimer's disease: systematic review, meta-analysis and quality assessment of cohort and case-control studies." (2022) — PMID 35301183 — Across 58 studies with over 1 year of follow-up, the relative risk for dementia associated with physical activity was 0.80 (0.86 for Alzheimer's and 0.79 for vascular dementia), which was maintained even at follow-ups exceeding 20 years despite potential publication bias, leading the authors to support physical activity as a modifiable protective factor even after minimizing reverse causation.
• "Trials and Treatments for Vascular Brain Health: Risk Factor Modification and Cognitive Outcomes." (2022) — PMID 35000424 — Randomized trial evidence on cognitive outcomes from blood pressure, lipid, and diabetes treatments as well as multi-domain interventions is promising but inconclusive, with most studies involving older populations in high-income countries.
• "Diabetes and dementia: Clinical perspective, innovation, knowledge gaps." (2022) — PMID 36240668 — Type 2 diabetes is a modifiable risk factor that increases dementia risk, though whether diabetes medications reduce dementia risk remains uncertain.
• "Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care." (2025) — PMID 39713942 — Alzheimer's Association clinical practice guideline (primary care summary): all clinicians should use structured evaluations to identify cognitive functional status, syndromes, and underlying etiologies, and disclose findings to patients and accompanying caregivers.
• "Vascular dementia: From pathobiology to emerging perspectives." (2024) — PMID 38513772 — Vascular dementia is the second most common type of dementia, and its pathological mechanisms are not yet fully elucidated.
• "Delirium in the Elderly." (2020) — PMID 32222295 — Delirium is defined as an acute disturbance of attention and cognition, is strongly associated with morbidity and mortality, and requires multi-component non-pharmacological prevention and treatment.
• "Delirium." (2000) — PMID 10767881 — Delirium is a true medical emergency that can mimic chronic dementia or functional psychosis and mask underlying medical illness or intoxication, and is uncovered through history and examination (2000 emergency department review).
• "Broadening dementia risk models: building on the 2024 Lancet Commission report for a more inclusive global framework." (2025) — PMID 41004922 — The 2024 Lancet Commission report estimated that 14 modifiable risk factors account for approximately 45% of worldwide dementia (a review citing and expanding upon these findings—the authors' expanded estimates are not used in the main text).